<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882984</url>
  </required_header>
  <id_info>
    <org_study_id>Hybrid</org_study_id>
    <nct_id>NCT02882984</nct_id>
  </id_info>
  <brief_title>Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)</brief_title>
  <acronym>Hybrid</acronym>
  <official_title>Comparing Whole Brain Radiation With Hypofractionated Stereotactic RadioSurgery (HFSRS) in Patients With NSCL Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center phase III randomized controlled study to evaluate the efficacy of
      Hypofractionated SRS (HFSRS) along with EGFR-TKI in patients with brain metastasis from
      non-small cell lung cancer (NSCLC). Assuming that HFSRS is not inferior to EGFR-TKI
      concurrent with whole brain radiotherapy (WBRT), the primary end point is intracranial PFS
      (iPFS), while secondary outcomes included overall survival (OS), evaluation of cognitive
      function, quality of life (QoL) and adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      WBRT remains to be standard of care for NSCL patients. Long term survival from WBRT may have
      noticeable cognitive dysfunction. The EGFR TKI has reasonable control for intracranial
      disease, but the duration of EGFR TKI control disease is variable due to tendency of drug
      resistance. To maintain intracranial disease control and improve cognitive function, the
      investigators propose using hypofractionated SRS in multiple brain metastases or large brain
      lesions alone with TKI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iPFS</measure>
    <time_frame>18 months</time_frame>
    <description>intracranial progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cognitive function</measure>
    <time_frame>18 month</time_frame>
    <description>Neurocognitive effects evaluated according to Mini-Mental Status Examination Evaluated according to Mini-Mental Status Examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>18 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">325</enrollment>
  <condition>Stage IV EGFR Mutated NSCL With Brain Metastases</condition>
  <arm_group>
    <arm_group_label>WBRT along with TKI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: EGFR-TKI
Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
Other Name: Gefitinib/Tarceva/Icotinib
Radiation: whole brain radiotherapy
3750Gy/15F
Other Name: WBRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFSRS with EGFR TKI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: EGFR-TKI
Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
Other Name: Gefitinib/Tarceva/Icotinib
Radiation: whole brain radiotherapy
25 to 40 Gy/5F
Other Name: HFSRS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib</intervention_name>
    <description>radiation given along with one of kind TKI</description>
    <arm_group_label>WBRT along with TKI</arm_group_label>
    <arm_group_label>HFSRS with EGFR TKI</arm_group_label>
    <other_name>EGFR-TKI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>WBRT</intervention_name>
    <description>3750 cGy in 15 fractions given within 3 weeks time.</description>
    <arm_group_label>WBRT along with TKI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HFSRS</intervention_name>
    <description>All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.</description>
    <arm_group_label>HFSRS with EGFR TKI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological confirmation of non-small cell lung cancer (NSCLC);

          -  Diagnosis of brain metastases on a Gadolinium-enhanced MRI.

          -  More than 3 sites of intracranial metastases, or the longest diameter of the
             intracranial lesion is more than 4 cm.

          -  Positive EGFR mutation.

          -  Life expectancy ≥3months.

          -  Have one or more measurable encephalic lesions according to RECIST.

          -  Adequate hematological function: Absolute neutrophil count (ANC) ≥1.5 x 109/L, and
             Platelet count ≥100 x 109/L.

          -  Adequate renal function: Serum creatinine ≤1.5 x ULN, or ≥ 50 ml/min.

          -  Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN) and
             Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) &lt; 2.5 x ULN in the
             absence of liver metastases, or &lt; 5 x ULN in case of liver metastases.

          -  Female subjects should not be pregnant.

          -  All human subjects should able to comply with the required protocol and follow-up
             procedures, and able to receive oral medications.

          -  Written informed consent provided.

        Exclusion Criteria:

          -  Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin,
             erbitux.

          -  CSF or MRI findings consistent with metastases of spinal cord, meninges or meningeal.

          -  Allergic to Icotinib.

          -  Lack of physical integrity of the upper gastrointestinal tract, or malabsorption
             syndrome, or inability to take oral medication, or have active peptic ulcer disease.

          -  Pregnancy or breast-feeding women.

          -  Participate in the other anti-tumor clinical trials in 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Zeng, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sichuan Provincial People Hospital, Sichuan Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YiFeng Bai, MD PhD</last_name>
    <phone>008618183298718</phone>
    <email>15756285949@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ming zeng, MD PhD</last_name>
    <phone>17708131336</phone>
    <email>miller2002@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sichuan PPH, Cancer Center</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>710062</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yifeng Bai, MD PhD</last_name>
      <phone>18183298718</phone>
      <email>15756285949@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Ming zeng, MD PhD</last_name>
      <phone>008617708131336</phone>
      <email>miller2002@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>ming zeng, MD</investigator_full_name>
    <investigator_title>Director of Cancer Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

